January 31, 2018
Justifying ROI for QbD
Bikash Chatterjee, President & CSO
Within the last year we have seen our share of quality issues hit the airwaves. The troubles in India with Ranbaxy and Wockhardt have spurred some excellent discussion of how to drive the concepts of quality home within pharma.
September 30, 2018
Quality Circle: Profitability, Integrity and the Cost of Poor Quality
Bikash Chatterjee, President & CSO
As major blockbuster drugs come off patent, the scramble among generics to capture these new markets is just beginning. We can expect the U.S. market to experience continued change and consolidation with cost cutting remaining at the top of the priority list for big pharma.